Livongo Health’s (NASDAQ:LVGO) lock-up period is set to end on Tuesday, January 21st. Livongo Health had issued 12,687,000 shares in its initial public offering on July 25th. The total size of the offering was $355,236,000 based on an initial share price of $28.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

Several equities analysts have recently weighed in on LVGO shares. ValuEngine downgraded shares of Livongo Health from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Piper Jaffray Companies raised their price target on shares of Livongo Health from $40.00 to $41.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Canaccord Genuity reissued a “buy” rating and issued a $46.00 price target on shares of Livongo Health in a research note on Monday, December 16th. Finally, Zacks Investment Research downgraded shares of Livongo Health from a “buy” rating to a “hold” rating in a research note on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $42.82.

Shares of LVGO stock opened at $29.45 on Tuesday. The stock’s 50-day moving average price is $26.70. Livongo Health has a 12 month low of $15.12 and a 12 month high of $45.68.

Livongo Health (NASDAQ:LVGO) last issued its earnings results on Wednesday, November 6th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.23. Livongo Health had a negative net margin of 43.59% and a negative return on equity of 119.92%. The company had revenue of $46.70 million for the quarter, compared to the consensus estimate of $42.77 million. During the same period in the previous year, the firm earned ($0.55) earnings per share. Livongo Health’s quarterly revenue was up 148.7% compared to the same quarter last year. As a group, equities analysts predict that Livongo Health will post -1.38 EPS for the current fiscal year.

In other news, Director Christopher Bischoff bought 4,000 shares of Livongo Health stock in a transaction on Monday, November 18th. The shares were bought at an average cost of $25.48 per share, with a total value of $101,920.00. Following the completion of the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at $101,920. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

A number of hedge funds have recently modified their holdings of LVGO. Partner Investment Management L.P. purchased a new position in Livongo Health during the third quarter worth about $25,000. Metropolitan Life Insurance Co NY acquired a new stake in shares of Livongo Health during the third quarter valued at about $149,000. Rhumbline Advisers acquired a new stake in shares of Livongo Health during the third quarter valued at about $238,000. Alpine Global Management LLC acquired a new stake in shares of Livongo Health during the fourth quarter valued at about $258,000. Finally, FNY Investment Advisers LLC increased its position in shares of Livongo Health by 5,330.0% during the fourth quarter. FNY Investment Advisers LLC now owns 10,860 shares of the company’s stock valued at $272,000 after acquiring an additional 10,660 shares during the last quarter. 18.45% of the stock is currently owned by institutional investors.

About Livongo Health

Livongo Health, Inc provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications.

Featured Story: Bond

Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with's FREE daily email newsletter.